MCID: SML001
MIFTS: 61

Small Cell Carcinoma

Categories: Cancer diseases, Genetic diseases, Rare diseases, Respiratory diseases, Skin diseases

Aliases & Classifications for Small Cell Carcinoma

MalaCards integrated aliases for Small Cell Carcinoma:

Name: Small Cell Carcinoma 12 15 17
Small Cell Carcinoma, Intermediate Cell 12 74
Small Cell Carcinoma - Intermediate Cell 12
Intermediate Cell Small Cell Carcinoma 12
Small Cell Carcinoma of Lung 74
Carcinoma, Small Cell 74

Classifications:



External Ids:

Disease Ontology 12 DOID:0050685
NCIt 51 C4099
SNOMED-CT 69 5958006

Summaries for Small Cell Carcinoma

Disease Ontology : 12 A carcinoma that is an undifferentiated neoplasm composed of primitive-appearing cells.

MalaCards based summary : Small Cell Carcinoma, also known as small cell carcinoma, intermediate cell, is related to lung combined type small cell carcinoma and ureter small cell carcinoma. An important gene associated with Small Cell Carcinoma is ENO2 (Enolase 2), and among its related pathways/superpathways are Endometrial cancer and Downstream signaling events of B Cell Receptor (BCR). The drugs Cisplatin and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include lung, prostate and brain, and related phenotypes are Decreased viability in esophageal squamous lineage and cellular

Related Diseases for Small Cell Carcinoma

Diseases in the Small Cell Carcinoma family:

Basal Cell Carcinoma 1 Basal Cell Carcinoma 2
Basal Cell Carcinoma 3 Basal Cell Carcinoma 4
Basal Cell Carcinoma 5 Basal Cell Carcinoma 6
Basal Cell Carcinoma 7 Basal Cell Carcinoma
Large Cell Carcinoma Basal Cell Carcinoma, Multiple

Diseases related to Small Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 515)
# Related Disease Score Top Affiliating Genes
1 lung combined type small cell carcinoma 34.4 NCAM1 SYP
2 ureter small cell carcinoma 34.4 CHGA SYP
3 gastric small cell carcinoma 33.7 CHGA ENO2 NCAM1 PTPRC SYP
4 gallbladder small cell carcinoma 33.6 CHGA ENO2 KRT7 NCAM1 SYP
5 small cell carcinoma of the bladder 33.6 CHGA ENO2 KRT20 KRT7 NKX2-1 SYP
6 prostate small cell carcinoma 33.5 ENO2 KIT KLK3 NKX2-1 PTEN
7 endometrial small cell carcinoma 33.4 ENO2 KIT NCAM1 PDGFRA PTPRC SYP
8 cervix small cell carcinoma 33.2 CDKN2A CHGA ENO2 NCAM1 SYP TP53
9 penile cancer 31.4 CDKN2A EGFR TP53
10 merkel cell carcinoma 31.1 CHGA ENO2 KIT KRT20 KRT7 NCAM1
11 small cell cancer of the lung 30.9 CALCA CDKN2A CHGA EGFR ENO2 KIT
12 adenocarcinoma 30.5 CDKN2A EGFR KIT PTEN TP53
13 pulmonary large cell neuroendocrine carcinoma 30.4 CHGA ENO2 SYP
14 carcinoid syndrome 30.4 CALCA CHGA ENO2 SYP
15 rhabdoid cancer 30.4 ENO2 SMARCA4 SYP TP53
16 ovarian mucinous neoplasm 30.2 KRT20 KRT7 SYP
17 achalasia 30.0 ENO2 KIT TP53
18 in situ carcinoma 30.0 CDKN2A EGFR TP53
19 tubular adenocarcinoma 30.0 CHGA KRT20 SYP
20 paraganglioma 30.0 CHGA ENO2 SYP
21 linitis plastica 30.0 KRT20 KRT7
22 follicular adenoma 29.9 CALCA NKX2-1 PTEN
23 lung oat cell carcinoma 29.9 CALCA CHGA ENO2
24 atypical teratoid rhabdoid tumor 29.9 SMARCA4 SYP TP53
25 mucinous cystadenocarcinoma 29.9 KRT20 KRT7 PTPRC
26 teratoma 29.7 ENO2 KIT KRT7 NKX2-1 SYP TP53
27 dermoid cyst 29.7 CHGA KIT KRT20 KRT7
28 barrett esophagus 29.6 CDKN2A KRT20 KRT7 TP53
29 pleomorphic carcinoma 29.6 EGFR KRT7 NKX2-1 TP53
30 rhabdomyosarcoma 29.6 ENO2 PDGFRA PTPRC TP53
31 cystic teratoma 29.6 ENO2 KRT20 KRT7 NKX2-1 SYP TP53
32 mesothelioma, malignant 29.5 CDKN2A KRT20 KRT7 NKX2-1
33 adenosquamous carcinoma 29.5 EGFR KIT KRT7 NKX2-1 TP53
34 large cell carcinoma 29.5 CHGA EGFR ENO2 KRT7 NCAM1 NKX2-1
35 large cell neuroendocrine carcinoma 29.5 CHGA EGFR ENO2 KIT KRT20 KRT7
36 mammary paget's disease 29.5 CALCA EGFR KRT20 KRT7
37 pheochromocytoma 29.4 CALCA CHGA ENO2 NCAM1 SYP
38 endocervical adenocarcinoma 29.4 CDKN2A KRT20 KRT7 TP53
39 cervical adenocarcinoma 29.4 CDKN2A KRT20 KRT7 TP53
40 pulmonary blastoma 29.4 CHGA EGFR NKX2-1 SYP TP53
41 suppression of tumorigenicity 12 29.4 CHGA KLK3 PTEN TP53
42 basaloid squamous cell carcinoma 29.4 CDKN2A EGFR ENO2 KRT7 SYP TP53
43 breast adenocarcinoma 29.4 CALCA EGFR PTEN TP53
44 li-fraumeni syndrome 29.4 CDKN2A EGFR PTEN TP53
45 renal cell carcinoma, nonpapillary 29.3 EGFR KIT KRT20 KRT7 NKX2-1
46 lung cancer susceptibility 3 29.3 CDKN2A EGFR KRT20 KRT7 NKX2-1 TP53
47 vulva cancer 29.3 CDKN2A EGFR KRT7 TP53
48 glioblastoma 29.1 CDKN2A EGFR PDGFRA PTEN TP53
49 adenoid cystic carcinoma 29.1 KIT KRT20 KRT7 PTEN SMARCA2 TP53
50 bladder urothelial carcinoma 29.1 KIT KLK3 KRT20 KRT7 TP53

Graphical network of the top 20 diseases related to Small Cell Carcinoma:



Diseases related to Small Cell Carcinoma

Symptoms & Phenotypes for Small Cell Carcinoma

GenomeRNAi Phenotypes related to Small Cell Carcinoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.32 CDKN2A CHGA KIT KLK3 KRT7 NKX2-1

MGI Mouse Phenotypes related to Small Cell Carcinoma:

47 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.39 CDKN2A EGFR ENO2 KIT KRT7 NCAM1
2 growth/size/body region MP:0005378 10.33 CDKN2A CHGA EGFR ENO2 KIT NKX2-1
3 homeostasis/metabolism MP:0005376 10.31 CDKN2A CHGA EGFR KIT KRT7 NKX2-1
4 endocrine/exocrine gland MP:0005379 10.3 CDKN2A CHGA EGFR KIT NKX2-1 PDGFRA
5 digestive/alimentary MP:0005381 10.27 CDKN2A EGFR KIT NKX2-1 PDGFRA PTEN
6 mortality/aging MP:0010768 10.27 CDKN2A CHGA EGFR KIT NCAM1 NKX2-1
7 nervous system MP:0003631 10.25 CDKN2A CHGA EGFR ENO2 KIT NCAM1
8 cardiovascular system MP:0005385 10.24 CDKN2A CHGA EGFR KIT NKX2-1 PDGFRA
9 neoplasm MP:0002006 10.16 CDKN2A EGFR KIT NKX2-1 PDGFRA PTEN
10 integument MP:0010771 10.13 CDKN2A EGFR KIT PDGFRA PTEN SMARCA2
11 muscle MP:0005369 10.13 CDKN2A CHGA EGFR KIT PDGFRA PTEN
12 liver/biliary system MP:0005370 10.05 CDKN2A EGFR KIT PTEN PTPRC SMARCA4
13 normal MP:0002873 10.02 EGFR KIT NKX2-1 PDGFRA PTEN PTPRC
14 no phenotypic analysis MP:0003012 10.01 CDKN2A CHGA EGFR KIT NKX2-1 PDGFRA
15 renal/urinary system MP:0005367 9.96 CHGA EGFR KIT KRT7 PDGFRA PTEN
16 reproductive system MP:0005389 9.81 CDKN2A CHGA EGFR KIT NKX2-1 PDGFRA
17 pigmentation MP:0001186 9.8 CDKN2A EGFR KIT PDGFRA PTEN TP53
18 respiratory system MP:0005388 9.65 CDKN2A EGFR ENO2 KIT NKX2-1 PDGFRA
19 skeleton MP:0005390 9.32 CDKN2A EGFR KIT NKX2-1 PDGFRA PTEN

Drugs & Therapeutics for Small Cell Carcinoma

Drugs for Small Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 484)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 441203 84093 2767
2
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
3
Irinotecan Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 100286-90-6, 97682-44-5 60838
4
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 38904 10339178 498142
5
Gefitinib Approved, Investigational Phase 4,Phase 2,Not Applicable 184475-35-2 123631
6
Dopamine Approved Phase 4,Phase 3,Phase 2 62-31-7, 51-61-6 681
7
Bupropion Approved Phase 4,Phase 3,Phase 2 34841-39-9, 34911-55-2 444
8
Nicotine Approved Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1 54-11-5 942 89594
9 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
11 topoisomerase I inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
12 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
14 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
15 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
16 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2
17 Dopamine Agents Phase 4,Phase 3,Phase 2
18 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
19 Antidepressive Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
20 Antidepressive Agents, Second-Generation Phase 4,Phase 3,Phase 2
21 Psychotropic Drugs Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
22 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 3,Phase 2
24 Dopamine Uptake Inhibitors Phase 4,Phase 3,Phase 2
25 Central Nervous System Stimulants Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1
26 Nicotinic Agonists Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1
27 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28 Cholinergic Agents Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1
29
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
30
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 6055-19-2, 50-18-0 2907
31
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
32
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
33
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
34
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
35
Temozolomide Approved, Investigational Phase 2, Phase 3,Phase 1 85622-93-1 5394
36
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1 51-75-2 4033
37
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 123948-87-8, 119413-54-6 60700
38
Dalteparin Approved Phase 3 9005-49-6
39
Heparin Approved, Investigational Phase 3,Phase 2 9005-49-6 772 46507594
40
Mesna Approved, Investigational Phase 3 3375-50-6 598
41
Vinorelbine Approved, Investigational Phase 3,Phase 1,Phase 2 71486-22-1 60780 44424639
42
Gemcitabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 95058-81-4 60750
43
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 114977-28-5 148124
44
Enoxaparin Approved Phase 3,Phase 2 9005-49-6 772
45
Bevacizumab Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 216974-75-3
46
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
47
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 1177-87-3
48
Durvalumab Approved, Investigational Phase 3,Phase 2,Phase 1 1428935-60-7
49
Niraparib Approved, Investigational Phase 3,Phase 1,Phase 2 1038915-60-4 24958200
50
Vincristine Approved, Investigational Phase 3,Phase 2 2068-78-2, 57-22-7 5978

Interventional clinical trials:

(show top 50) (show all 864)
# Name Status NCT ID Phase Drugs
1 Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer Unknown status NCT02348450 Phase 4 Irinotecan;Etoposide;Cisplatin
2 Clinical Study of First-line Treatment of Small Cell Lung Cancer (SCLC) With Anlotinib Hydrochloride Not yet recruiting NCT03890055 Phase 4 Anlotinib Hydrochloride
3 Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy Suspended NCT01720901 Phase 4 Icotinib
4 the Clinical Trial of Gefitinib(Non - Small Cell Lung Cancer) Not yet recruiting NCT03264794 Phase 4 Gefitinib Tab (CTTQ),First medication;Gefitinib Tab (CTTQ),From the 8th day of trial;Gefitinib tablets (Yi Ruisha),First medication;Gefitinib Tab 250 MG(CTTQ),From the 8th day of trial.
5 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
6 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
7 STAD-1 Small Cell Lung Cancer Toxicity Adjusted Dosing Study Unknown status NCT00526396 Phase 3 cisplatin;etoposide;cisplatin;etoposide
8 Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient Unknown status NCT00826644 Phase 3 Belotecan/Cisplatin;Etoposide/Cisplatin
9 Combination Chemotherapy in Treating Patients With Extensive Stage Small Cell Lung Cancer Unknown status NCT00003606 Phase 3 cisplatin;cyclophosphamide;epirubicin hydrochloride;etoposide
10 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Small Cell Lung Cancer Unknown status NCT00002858 Phase 3 cisplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide
11 Combination Chemotherapy in Treating Patients Who Have Extensive-Stage Small Cell Lung Cancer Unknown status NCT00003696 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;paclitaxel
12 Chemotherapy Followed by Peripheral Stem Cell or Bone Marrow Transplant Compared With Chemotherapy Alone in Treating Patients With Small Cell Lung Cancer Unknown status NCT00011921 Phase 3 carboplatin;epirubicin hydrochloride;etoposide;etoposide phosphate;ifosfamide;paclitaxel
13 Temozolomide as Maintenance Therapy Following Induction Chemotherapy in Extensive Stage Small Cell Lung Cancer Unknown status NCT02772107 Phase 2, Phase 3 Temozolomide;first-line chemotherapy
14 Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study) Unknown status NCT01555710 Phase 3 Carboplatin;Palifosfamide-tris;Etoposide;Carboplatin
15 Study of Picoplatin Efficacy After Relapse Unknown status NCT00465491 Phase 3 picoplatin
16 A Study for Small Cell Lung Cancer (SCLC) in Extensive Disease Stage Unknown status NCT00168896 Phase 2, Phase 3 Carboplatin plus Irinotecan vs Carboplatin plus Etoposide
17 A Prospective Randomized Study Comparing the Target Volume for Limited-stage Small Cell Lung Cancer Unknown status NCT01731548 Phase 2, Phase 3
18 SCLC on the 2nd Line With Relapsed After Response to Chemotherapy GFPC 01-2013 Unknown status NCT02738346 Phase 3 Carboplatin;Etoposide;Topotecan
19 Dalteparin in Preventing Blood Clots in Patients With Lung Cancer Unknown status NCT00519805 Phase 3 dalteparin
20 Apatinib as the Maintenance Therapy for Extensive Stage Small Cell Lung Cancer After Combined With Etoposide/Cisplatin Not yet recruiting NCT02875457 Phase 3 apatinib;etoposide and cisplatin;placebo;etoposide and cisplatin
21 A Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer Completed NCT00717938 Phase 3 cisplatinum or carboplatin and e.g.etoposide.;cisplatinum or carboplatin and e.g.etoposide+enoxaparin
22 Bevacizumab in Extensive Small Cell Lung Cancer Completed NCT00930891 Phase 2, Phase 3 Standard Chemotherapy (PCDE or PE);Experimental Treatment (PCDE or PE + bevacizumab);Prerandomization Chemotherapy (PCDE or PE)
23 AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy Completed NCT00547651 Phase 3 Amrubicin;Topotecan
24 Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC) Terminated NCT00286169 Phase 3 Amrubicin Hydrochloride
25 Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer Withdrawn NCT03334487 Phase 3 Dexamethasone;Rovalpituzumab tesirine
26 Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN) Active, not recruiting NCT03043872 Phase 3 Durvalumab;Tremelimumab;Carboplatin;Cisplatin;Etoposide
27 Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE) Active, not recruiting NCT03061812 Phase 3 Rovalpituzumab tesirine;Topotecan
28 A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer Recruiting NCT03516084 Phase 3 ZL-2306(nirapairb);Placebo
29 Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer Active, not recruiting NCT03098030 Phase 2, Phase 3 Irinotecan;Topotecan
30 Bronchoscopic Intratumoral Chemotherapy for Small Cell Lung Cancer (SCLC) Terminated NCT01487499 Phase 3 Cisplatin
31 Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) Versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer Active, not recruiting NCT02566993 Phase 3 Lurbinectedin (PM01183);Doxorubicin (DOX);Cyclophosphamide (CTX);Vincristine (VCR);Topotecan
32 Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer Recruiting NCT03088813 Phase 2, Phase 3 Irinotecan liposome injection;Topotecan
33 Early Versus Late Concurrent Chemoradiation for Limited Stage Small-cell Lung Cancer Completed NCT01125995 Phase 3
34 Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Treating Patients With Limited Stage or Extensive Stage Small Cell Lung Cancer Recruiting NCT02635009 Phase 2, Phase 3
35 Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone Completed NCT01450761 Phase 3 Etoposide;Cisplatin;Carboplatin
36 A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604) Active, not recruiting NCT03066778 Phase 3 Normal saline solution;Carboplatin;Cisplatin;Etoposide
37 Marimastat Following Chemotherapy in Treating Patients With Small Cell Lung Cancer Completed NCT00003011 Phase 3 marimastat;Placebo
38 A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin Alfa Completed NCT00119613 Phase 3 placebo;darbepoetin alfa
39 Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults Completed NCT00043927 Phase 3 topotecan/cisplatin;etoposide/cisplatin
40 Efficacy and Safety of Obatoclax Mesylate in Combination With Carboplatin and Etoposide Compared With Carboplatin and Etoposide Alone in Chemotherapy-Naive Patients With Extensive-Stage Small Cell Lung Cancer Withdrawn NCT01563601 Phase 3 Obatoclax Mesylate, Carboplatine and Etoposide;Carboplatin and Etoposide
41 Study Of Irinotecan Hydrochloride (Campto(R)) And Cisplatin Versus Etoposide And Cisplatin In Small Cell Lung Cancer Completed NCT00143455 Phase 3 Etoposide + cisplatin;Irinotecan + cisplatin
42 RRx-001 Prior to a Platinum Doublet or a Platinum Doublet Alone in Patients With Small Cell Carcinoma Recruiting NCT03699956 Phase 3 Cisplatin/carboplatin plus etoposide
43 Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer Completed NCT00363415 Phase 3 pemetrexed;etoposide;carboplatin
44 Radiation Therapy in Preventing Brain Metastases in Patients With Small Cell Lung Cancer Withdrawn NCT00006344 Phase 3
45 Discovery Stage IND EXEMPT Clinical Study - Etoposide Plus Methotrexate and Single Nucleotide Polymorphisms Active, not recruiting NCT03305341 Phase 3 Etoposide Injection plus Methotrexate Injection;Etoposide Capsule plus Methotrexate Tablet
46 Discovery Stage IND EXEMPT Clinical Study - Etoposide OS Plus Methotrexate OS and Single Nucleotide Polymorphisms Active, not recruiting NCT03348670 Phase 3 Etoposide Capsule + Methotrexate Tablet + Topotecan Capsule;Etoposide Capsule + Methotrexate Tablet + Everolimus Tablet
47 Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy Recruiting NCT03703297 Phase 3 Durvalumab;Tremelimumab
48 Randomized Study of Cisplatin-Etoposide Versus an Etoposide Regimen Without Cisplatin in Extensive Small-Cell Lung Cancer Completed NCT00658580 Phase 3 Cisplatin + etoposide;Epirubicin + ifosfamide + etoposide
49 A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU) Recruiting NCT03033511 Phase 3 Placebo for dexamethasone;Placebo for rovalpituzumab tesirine;Rovalpituzumab tesirine;Dexamethasone
50 Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide Recruiting NCT00632853 Phase 3 cisplatin;etoposide;carboplatin

Search NIH Clinical Center for Small Cell Carcinoma

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Genetic Tests for Small Cell Carcinoma

Anatomical Context for Small Cell Carcinoma

MalaCards organs/tissues related to Small Cell Carcinoma:

42
Lung, Prostate, Brain, Ovary, Cervix, Bone, Bone Marrow

Publications for Small Cell Carcinoma

Articles related to Small Cell Carcinoma:

(show top 50) (show all 2473)
# Title Authors Year
1
Transformation of epidermal growth factor receptor T790M mutation-positive adenosquamous carcinoma of the lung to small cell carcinoma and large-cell neuroendocrine carcinoma following osimertinib therapy: an autopsy case report. ( 30828454 )
2019
2
Paraneoplastic limbic encephalitis revealing a small cell carcinoma of the lung. ( 30622890 )
2019
3
Large Cell Neuroendocrine Carcinoma Shares Similarity with Small Cell Carcinoma on the Basis of Clinical and Pathological Features. ( 30818166 )
2019
4
Corrigendum: Treatment-refractory paraneoplastic opsoclonus-myoclonus syndrome in a patient with small cell carcinoma of the lung. ( 30907284 )
2019
5
Treatment-refractory paraneoplastic opsoclonus-myoclonus syndrome in a patient with small-cell carcinoma of the lung. ( 30791855 )
2019
6
An In-Depth Look at Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT): Clinical Implications from Recent Molecular Findings. ( 30662543 )
2019
7
CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary. ( 30718512 )
2019
8
Small cell carcinoma of cervix: A population-based study evaluating standardized provincial treatment protocols. ( 30723760 )
2019
9
Primary small cell carcinoma of the esophagus: Comparison between a Chinese cohort and Surveillance, Epidemiology, and End Results (SEER) data. ( 30740907 )
2019
10
First Case of Cellular Cannibalism in Small-Cell Carcinoma of the Bladder Detected in Peripheral Blood. ( 30809987 )
2019
11
Cytologic diagnosis of small cell carcinoma of the ovary: A case report with review of the literature. ( 30821422 )
2019
12
Small cell carcinoma of the kidney: a case report and analysis of data from the Surveillance, Epidemiology, and End Results registry. ( 30841901 )
2019
13
Primary small cell carcinoma of the vagina: a rare instance of prolonged survival. ( 30852510 )
2019
14
Survival outcomes after whole brain radiotherapy for brain metastases in older adults with newly diagnosed metastatic small cell carcinoma: A national cancer database (NCDB) analysis. ( 30876834 )
2019
15
The dilemma of early preventive oophorectomy in familial small cell carcinoma of the ovary of hypercalcemic type. ( 30886884 )
2019
16
Cytopathologic characteristics of HPV-related small cell carcinoma of the oropharynx. ( 30468701 )
2019
17
Prognostic Role of S100A8 and S100A9 Protein Expressions in Non-small Cell Carcinoma of the Lung. ( 30472816 )
2019
18
Primary small cell carcinoma of the ureter: Case report and review of the literature. ( 29901633 )
2018
19
Primary Mammary Small Cell Carcinoma. ( 29866240 )
2018
20
Immunohistochemical expression and prognostic value of PD-L1 in Extrapulmonary small cell carcinoma: a single institution experience. ( 29843803 )
2018
21
Small cell carcinoma of the stomach: A report of two cases and a review of the literature. ( 29896397 )
2018
22
Advanced small cell carcinoma of the cervix - Successful treatment with concurrent etoposide and cisplatin chemotherapy and extended field radiation: A case report and discussion. ( 29255785 )
2018
23
The use of adaptive intensity-modulated radiotherapy in the treatment of small-cell carcinoma lung refractory to chemotherapy in a patient with preexisting interstitial lung disease. ( 29319036 )
2018
24
Ovarian Small Cell Carcinoma: A Rare Case Report and Review of Literature. ( 29731803 )
2018
25
Insulinoma-Associated Protein 1 Immunostain: A Diagnostic Tool for Pulmonary Small Cell Carcinoma in Cytology. ( 29936498 )
2018
26
Identification of Driver Mutations in Rare Cancers: The Role of SMARCA4 in Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT). ( 29423809 )
2018
27
Insulinoma-associated protein 1 is a novel sensitive and specific marker for small cell carcinoma of the prostate. ( 29885405 )
2018
28
Cytological features of small cell carcinoma of the ovary-hypercalcemic type/malignant ovarian rhabdoid tumor in ascitic fluid. ( 29446248 )
2018
29
Successful treatment of a stage IIIC small-cell carcinoma of the ovary hypercalcemic subtype using multi-modality therapeutic approach. ( 29910829 )
2018
30
Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade. ( 29365144 )
2018
31
Surgery for limited-stage primary small cell carcinoma of the esophagus: is it feasible and for whom is it indicated? ( 29849202 )
2018
32
Comments on "Treatment Strategies and Prognostic Factors of Limited-Stage Primary Small Cell Carcinoma of the Esophagus". ( 29425616 )
2018
33
Primary ovarian small cell carcinoma of pulmonary type with coexisting endometrial carcinoma in a breast cancer patient receiving tamoxifen: A case report and literature review. ( 29879027 )
2018
34
Small-Cell Carcinoma Transformation of Pulmonary Adenocarcinoma after Osimertinib Treatment: A Case Report. ( 29928211 )
2018
35
Primary Gastric Small Cell Carcinoma: A Case Identified as a Large Subepithelial Tumor from Invisible State in 6 Months. ( 29976037 )
2018
36
Small cell carcinoma of the urinary bladder: a Clinicopathologic and Immunohistochemical analysis of 81 cases. ( 29763719 )
2018
37
Intravesical recurrence after bladder sparing treatment of small cell carcinoma of the bladder: Characteristics, treatment, and outcome. ( 29580697 )
2018
38
Response to "Comments on Treatment Strategies and Prognostic Factors of Limited-Stage Primary Small Cell Carcinoma of the Esophagus". ( 29425617 )
2018
39
Tonsillar Small Cell Carcinoma: Potential Contribution of Human Papillomavirus. ( 29686221 )
2018
40
Nomograms to Predict Individual Prognosis of Patients with Primary Small Cell Carcinoma of the Bladder. ( 29675096 )
2018
41
Lambert-Eaton Myasthenic Syndrome Associated with Synchronous Double Cancer: A Combination of Small Cell Carcinoma of the Cervix and Breast Carcinoma. ( 29526952 )
2018
42
Combined small cell carcinoma with giant cell carcinoma component of the lung: A case successfully diagnosed by computed tomography-guided fine-needle aspiration cytology. ( 29399198 )
2018
43
Primary small cell carcinoma of the larynx. Survival time of 47 months. Case report. ( 29946458 )
2018
44
Extrapulmonary small cell carcinoma: an unfortunate case of metastatic disease. ( 29309906 )
2018
45
Concomitant small cell carcinoma and adenocarcinoma of the gallbladder: a case report. ( 29923489 )
2018
46
Dual Paraneoplastic Endocrine Syndromes Heralding Onset of Extrapulmonary Small Cell Carcinoma: A Case Report and Narrative Review. ( 29755405 )
2018
47
The genomic landscape of small cell carcinoma of the esophagus. ( 29728688 )
2018
48
Evaluating Treatment Patterns for Small Cell Carcinoma of the Colon Using the National Cancer Database (NCDB). ( 29354876 )
2018
49
Cervical small cell carcinoma frequently presented in multiple high risk HPV infection and often associated with other type of epithelial tumors. ( 29788963 )
2018
50
Ponatinib shows potent antitumor activity in small cell carcinoma of the ovary hypercalcemic type (SCCOHT) through multi-kinase inhibition. ( 29440177 )
2018

Variations for Small Cell Carcinoma

Expression for Small Cell Carcinoma

Search GEO for disease gene expression data for Small Cell Carcinoma.

Pathways for Small Cell Carcinoma

Pathways related to Small Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.66 CDKN2A EGFR KIT KLK3 PDGFRA PTEN
2
Show member pathways
12.57 EGFR KIT PDGFRA PTEN TP53
3
Show member pathways
12.55 CDKN2A EGFR PDGFRA PTEN TP53
4 12.53 CDKN2A EGFR KIT KLK3 PDGFRA PTEN
5 12.41 CALCA ENO2 NCAM1 NKX2-1 SYP
6
Show member pathways
12.38 EGFR PDGFRA PTEN TP53
7
Show member pathways
12.37 CDKN2A EGFR KIT PTEN SMARCA2 SMARCA4
8 12.31 CDKN2A EGFR PDGFRA PTEN TP53
9
Show member pathways
12.09 EGFR PDGFRA PTEN TP53
10 11.98 EGFR PDGFRA PTEN TP53
11 11.98 EGFR PTEN SMARCA4 TP53
12 11.88 EGFR PTEN SMARCA4 TP53
13 11.75 EGFR KLK3 PTEN
14
Show member pathways
11.69 SMARCA2 SMARCA4 TP53
15 11.67 KIT NCAM1 PTPRC
16 11.63 KIT NCAM1 PTPRC
17 11.62 CDKN2A EGFR TP53
18 11.6 NCAM1 PDGFRA SMARCA4 SYP
19
Show member pathways
11.59 EGFR SMARCA2 SMARCA4
20 11.54 PTEN SMARCA2 TP53
21 11.41 KIT NCAM1 PDGFRA
22 11.4 CDKN2A EGFR PDGFRA PTEN TP53
23 11.33 CDKN2A EGFR PDGFRA TP53
24 10.83 EGFR KIT PDGFRA PTEN TP53

GO Terms for Small Cell Carcinoma

Cellular components related to Small Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 npBAF complex GO:0071564 8.96 SMARCA2 SMARCA4
2 cytoplasmic side of plasma membrane GO:0009898 8.8 KIT PTEN PTPRC

Biological processes related to Small Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.85 CDKN2A EGFR NKX2-1 SMARCA2 SMARCA4 TP53
2 positive regulation of gene expression GO:0010628 9.83 CDKN2A KIT NKX2-1 PTEN TP53
3 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.77 EGFR KIT PDGFRA
4 MAPK cascade GO:0000165 9.76 EGFR KIT NCAM1 PDGFRA
5 lung development GO:0030324 9.75 EGFR NKX2-1 PDGFRA
6 negative regulation of apoptotic process GO:0043066 9.74 EGFR PTEN TP53
7 negative regulation of transcription, DNA-templated GO:0045892 9.73 CALCA CDKN2A NKX2-1 SMARCA2 SMARCA4 TP53
8 mast cell degranulation GO:0043303 9.58 CHGA KIT
9 positive regulation of phospholipase C activity GO:0010863 9.56 KIT PDGFRA
10 replicative senescence GO:0090399 9.55 CDKN2A TP53
11 tongue development GO:0043586 9.54 EGFR KIT
12 cerebral cortex cell migration GO:0021795 9.52 EGFR NKX2-1
13 Leydig cell differentiation GO:0033327 9.51 NKX2-1 PDGFRA
14 positive regulation of MAPK cascade GO:0043410 9.5 KIT PDGFRA PTPRC
15 somatic stem cell division GO:0048103 9.49 CDKN2A KIT
16 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.48 EGFR TP53
17 negative regulation of cell growth GO:0030308 9.46 CDKN2A SMARCA2 SMARCA4 TP53
18 mast cell chemotaxis GO:0002551 9.4 CHGA KIT
19 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.02 EGFR KIT PDGFRA PTEN PTPRC
20 mast cell cytokine production GO:0032762 8.96 CHGA KIT

Molecular functions related to Small Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.65 CDKN2A EGFR PTEN PTPRC TP53
2 nucleotide binding GO:0000166 9.55 EGFR KIT PDGFRA SMARCA2 SMARCA4
3 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.5 EGFR KIT PDGFRA
4 hydrolase activity, acting on acid anhydrides GO:0016817 9.37 SMARCA2 SMARCA4
5 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.13 EGFR KIT PDGFRA
6 Ras guanyl-nucleotide exchange factor activity GO:0005088 8.92 EGFR KIT NCAM1 PDGFRA

Sources for Small Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....